Fig. 1: Trial profile and clinical response.

a,b, Patient dispositions (a) and best percent change from baseline in sum of target lesions in patients with confirmed response (b). ^aOne patient did not receive leucovorin owing to institutional standard practice, but they did receive all other assigned study treatments. ^bOne patient is ongoing on leucovorin and fluorouracil but has discontinued domvanalimab and zimberelimab due to completion of the 2-year maximum treatment duration. The dashed reference lines indicate a 20% increase or 30% decrease from baseline in the sum of target lesions.